Walid Macaron

9PUBLICATIONS
40CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Medical bacteriologyHaematological tumoursMedical virologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 27, 2026
Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML.

|Mar 29, 2024
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.

Yaqi Zhao, Nicholas J Short, Hagop M Kantarjian

|May 15, 2023
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.

Nicholas J Short, Elias Jabbour, Walid Macaron

|Sep 10, 2022
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.

Sangeetha Venugopal, Courtney D DiNardo, Sanam Loghavi

|Sep 02, 2022
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission.

Nicholas J Short, Walid Macaron, Tapan Kadia

|May 09, 2022
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse.

Nicholas J Short, Hagop Kantarjian, Farhad Ravandi

Pageof 2

Frequent Collaborators

8 joint publications

Nicholas J Short

6 joint publications

Marina Konopleva

6 joint publications

Musa Yilmaz

4 joint publications

Farhad Ravandi